A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population

Indian Journal of Dermatology, Venereology and Leprology

Volumn 79, Issue 3, 2013, Pages 389-398

  Patel, Tejas K ^a   Barvaliya, Manish J ^b   Sharma, Dineshchandra ^a   Tripathi, Chandrabhanu ^b  

^a Baroda Medical College   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Causative drugs; corticosteroids; India; SCORTEN score; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

AMOXICILLIN; AMPICILLIN; AMPICILLIN PLUS CLOXACILLIN; CARBAMAZEPINE; CEFALEXIN; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CHLOROQUINE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; NEVIRAPINE; OFLOXACIN; PARACETAMOL; PEFLOXACIN; PENICILLIN DERIVATIVE; PHENYTOIN; PYRAZINAMIDE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; RIFAMPICIN; STAVUDINE; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BLEPHARITIS; BRAIN HEMORRHAGE; BREAST CARCINOMA; COMORBIDITY; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CORNEA DISEASE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRY EYE; ECONOMIC ASPECT; EMBASE; EOSINOPENIA; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPYON; INDIAN; LENGTH OF STAY; LEUKOCYTOSIS; LEUKOPENIA; LUNG EDEMA; LYMPHOCYTOPENIA; MEDLINE; METABOLIC ENCEPHALOPATHY; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; PNEUMONIA; SCAR FORMATION; SECONDARY INFECTION; SEPTICEMIA; STEROID THERAPY; STEVENS JOHNSON SYNDROME; SYMBLEPHARON; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; FLUOROQUINOLONES; HUMANS; INDIA; STEVENS-JOHNSON SYNDROME;

EID: 84877141602     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.110749     Document Type: Article

References (55)

1. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-7
2. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 1991;127:831-8
3. Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42
4. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85
5. Sehgal VN, Srivastava G. Toxic epidermal necrolysis (TEN) Lyell's syndrome. J Dermatolog Treat 2005;16:278-86
6. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6
7. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39
8. Saha K. Toxic epidermal necrolysis: Current concepts in pathogenesis and treatment. Indian J Dermatol Venereol Leprol 2000;66:10-7
9. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008;7:598-605
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9
11. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Epidemiology 2007;18:805-35
12. Central Drugs Standard Control Organization (Medical devices division). Guidance document on application for grant of Licence in Form-28 for manufacture of Medical Devices in India under CLAA Scheme, 2010. Available from: Http://cdsco. nic.in/Guidance%20document%20on%20application%20 for%20grant%20of%20Licence%20in%20Form-28%20 for%20manufacture%20of%20Medical%20Devices%20rffrt in%20India%20under%20CLAA%20Scheme.PDF [Last cited 2012 Jan 11].
13. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: Clinical pattern and causative agents -A 6 year series from Chandigarh, India. J Postgrad Med 2001;47:95-9
14. Noel MV, Sushma M, Guido S. Cutaneous adverse drug reactions in hospitalized patients in a tertiary care center. Indian J Pharmacol 2004;36:292-5
15. Sushma M, Noel MV, Ritika MC, James J, Guido S. Cutaneous adverse drug reactions: A 9-year study from a South Indian Hospital. Pharmacoepidemiol Drug Saf 2005;14:567-70
16. Chatterjee S, Ghosh AP, Barbhuiya J, Dey SK. Adverse cutaneous drug reactions: A one year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian J Pharmacol 2006;38:429-31
17. Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine -The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years. Indian J Dermatol Venereol Leprol 2005;71:325-8
18. Vaishampayan SS, Das AL, Verma R. SCORTEN: Does it need modification? Indian J Dermatol Venereol Leprol 2008;74:35-7
19. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: A retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008;74:238-40
20. Shrivastava M, Uchit G, Chakravarti A, Joshi G, Mahatme M, Chaudhari H. Adverse drug reactions reported in Indira Gandhi Government Medical College and Hospital, Nagpur. J Assoc Physicians India 2011;59:296-9
21. Sanmarkan AD, Sori T, Thappa DM, Jaisankar TJ. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis over a period of 10 years. Indian J Dermatol 2011;56:25-9
22. Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: A multicentric retrospective study. J Postgrad Med 2011;57:115-9
23. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53
24. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007;56:419-25
25. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44
26. Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim- sulfamethoxazole. J Am Acad Dermatol 2009;60:589-94
27. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: Treatment outcomes. Acta Derm Venereol 2012;92:62-6
28. Saka B, Kombaté K, Mouhari-Toure A, Akakpo S, Tchangai-Walla K, Pitché P. Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: Retrospective study of 89 cases. Med Trop (Mars) 2010;70:255-8
29. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7
30. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC, EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-8
31. Pitche P, Mouzou T, Padonou C, Tchangai-Walla K. Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: Report of 8 cases in HIV-infected patients in Togo. Med Trop (Mars) 2005;65:359-62
32. Radhakrishnan K, Nayak SD, Kumar SP, Sarma PS. Profile of antiepileptic pharmacotherapy in a tertiary referral center in South India: A pharmacoepidemiologic and pharmacoeconomic study. Epilepsia 1999;40:179-85
33. Mathur S, Sen S, Ramesh L, Kumar S. Utilization pattern of antiepileptic drugs and their adverse effects, in a teaching hospital. Asian J Pharm Clin Res 2010;3:55-9
34. Yang CY, Dao RL, Lee TJ, Lu CW, Yang CH, Hung SI, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011;77:2025-33
35. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999;353:2190-4
36. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-8
37. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A pooled analysis. Pediatrics 2009;123:e297-304
38. Gupta M, Malhotra S, Jain S, Aggarwal A, Pandhi P. Pattern of prescription of non-steroidal antiinflammatory drugs in orthopaedic outpatient clinic of a north Indian tertiary care hospital. Indian J Pharmacol 2005;37:404-5
39. Paul AD, Chauhan CK. Study of usage pattern of nonsteroidal anti-inflammatory drugs (NSAIDs) among different practice categories in Indian clinical setting. Eur J Clin Pharmacol 2005;60:889-92
40. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004;428:86
41. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, et al. A marker for Stevens-Johnson syndrome: Ethnicity matters. Pharmacogenomics J 2006;6:265-8
42. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B. 1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-6
43. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B.*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009;75:579-82
44. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349-56
45. Kannenberg SM, Jordaan HF, Koegelenberg CF, Von Groote-Bidlingmaier F, Visser WI. Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: A 3-year prospective study. QJM 2012;105:839-46
46. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-8
47. Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schöpf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993;129:1059
48. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60
49. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et al. The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010;36:222-31
50. Castellanos-Ortega A, Suberviola B, Garcia-Astudillo LA, Holanda MS, Ortiz F, Llorca J, et al. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study. Crit Care Med 2010;38:1036-43
51. Yap FB, Wahiduzzaman M, Pubalan M. Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) in Sarawak: A four years' review. Egypt Dermatol Online J 2008;4:1-13
52. Guégan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272-6
53. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev 2002:CD001435
54. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007;87:144-8
55. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol 2011;18:e121-33